Resectable Non-small Cell Lung Cancer

Also known as: Resectable Non-Small-Cell Lung Cancer

Drug	Drug Name	Drug Description
DB09035	Nivolumab	A PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma.
DB09037	Pembrolizumab	A PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma.

Drug	Drug Name	Target	Type
DB09035	Nivolumab	Programmed cell death protein 1	target
DB09035	Nivolumab	Programmed cell death 1 ligand 1	target
DB09037	Pembrolizumab	Programmed cell death protein 1	target
DB09037	Pembrolizumab	Programmed cell death 1 ligand 1	target

Drug	Drug Name	Phase	Status	Count
DB15568	Adagrasib	2	Recruiting	1
DB00958	Carboplatin	2	Not Yet Recruiting	2
DB00958	Carboplatin	2	Recruiting	1
DB14707	Cemiplimab	2	Not Yet Recruiting	1
DB00515	Cisplatin	2	Not Yet Recruiting	2
DB00515	Cisplatin	2	Recruiting	1
DB01248	Docetaxel	2	Recruiting	1
DB17506	Etrumadenant	2	Recruiting	1
DB09035	Nivolumab	2	Recruiting	2
DB01229	Paclitaxel	2	Not Yet Recruiting	2
DB01229	Paclitaxel	2	Recruiting	1
DB00642	Pemetrexed	2	Not Yet Recruiting	1
DB00642	Pemetrexed	2	Recruiting	1
DB12893	Sacituzumab govitecan	2	Recruiting	1
DB17505	Zimberelimab	2	Recruiting	1
DB09035	Nivolumab	Not Available	Recruiting	1
DB12257	Platinum	Not Available	Recruiting	1